Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.

Journal for immunotherapy of cancer - 1 Jul 2020

He Bingxi, Dong Di, She Yunlang, Zhou Caicun, Fang Mengjie, Zhu Yongbei, Zhang Henghui, Huang Zhipei, Jiang Tao, Tian Jie, Chen Chang

Abstract excerpt

BACKGROUND: Tumor mutational burden (TMB) is a significant predictor of immune checkpoint inhibitors (ICIs) efficacy. This study investigated the correlation between deep learning radiomic biomarker and TMB, including its predictive value for ICIs treatment response in patients with advanced non-small-cell lung cancer (NSCLC). METHODS: CT images from 327 patients with TMB data (TMB median=6.067 mutations per...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 32636239
DOI: 10.1136/jitc-2020-000550
PMCID: PMC7342823

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.PMID 32636239Read ↗

Non-invasive decision support for NSCLC treatment using PET/CT radiomics.Semantic proximity Read ↗

The Predictive efficacy of tumor mutational burden for immune Checkpoint Inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trialsSemantic proximity Read ↗

Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

Correlation Between Tumor Mutational Burden and CT Radiographic Features in Lung Adenocarcinoma: A Diagnostic Accuracy StudySemantic proximity Read ↗

Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Hypoxia-related radiomics predict immunotherapy response: A multi-cohort study of NSCLCSemantic proximity Read ↗

The association of efficacy with PD-1/PD-L1 inhibition and tumor mutational burden in advanced nonsmall cell lung cancer: A PRISMA-guided literature review and meta-analysis.Semantic proximity Read ↗

Deep learning to estimate response of concurrent chemoradiotherapy in non-small-cell lung carcinomaSemantic proximity Read ↗

Habitat radiomics and deep learning fusion nomogram to predict EGFR mutation status in stage I non-small cell lung cancer: a multicenter study.Semantic proximity Read ↗

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.Semantic proximity Read ↗

Predicting PD-L1 expression in advanced EGFR-mutant lung adenocarcinoma patients using NECT, CECT radiomics and clinical features.Semantic proximity Read ↗

Deep learning radiomics for the prediction of epidermal growth factor receptor mutation status based on MRI in brain metastasis from lung adenocarcinoma patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.